Elanco Animal Health Incorporated (NYSE:ELAN) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Elanco Animal Health has received a consensus recommendation of "Moderate Buy" from analysts, with three holding a neutral stance, six giving buy ratings, and two assigning strong buy ratings.
• The average 12-month price objective set by analysts for Elanco is $19.14, reflecting a positive outlook for the stock's performance.
• Elanco reported a quarterly earnings per share (EPS) of $0.26, exceeding analyst expectations and indicating a 4.8% year-over-year revenue growth.

Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven ratings firms that are covering the company, MarketBeat reports. Three analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $19.1429.

ELAN has been the subject of several research reports. William Blair raised Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research note on Thursday, June 26th. UBS Group raised their price objective on Elanco Animal Health from $18.00 to $19.00 and gave the stock a "buy" rating in a research note on Friday, August 8th. Wall Street Zen raised Elanco Animal Health from a "hold" rating to a "buy" rating in a research note on Saturday, July 5th. Zacks Research raised Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research note on Friday, October 3rd. Finally, Stifel Nicolaus raised their price objective on Elanco Animal Health from $18.00 to $23.00 and gave the stock a "buy" rating in a research note on Wednesday, September 24th.

Elanco Animal Health Stock Performance

Shares of NYSE ELAN opened at $19.77 on Friday. The stock has a fifty day moving average price of $18.35 and a two-hundred day moving average price of $14.43. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.40 and a current ratio of 2.60. The firm has a market cap of $9.82 billion, a P/E ratio of 22.99, a PEG ratio of 3.64 and a beta of 1.65. Elanco Animal Health has a 1 year low of $8.02 and a 1 year high of $21.76.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.20 by $0.06. The firm had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.19 billion. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The firm's quarterly revenue was up 4.8% on a year-over-year basis. During the same period last year, the company posted $0.30 EPS. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Research analysts forecast that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Institutional Investors Weigh In On Elanco Animal Health

Several large investors have recently modified their holdings of ELAN. GAMMA Investing LLC lifted its holdings in shares of Elanco Animal Health by 1,743.8% in the first quarter. GAMMA Investing LLC now owns 12,390 shares of the company's stock valued at $130,000 after purchasing an additional 11,718 shares in the last quarter. Yousif Capital Management LLC purchased a new stake in shares of Elanco Animal Health in the first quarter valued at $119,000. SG Americas Securities LLC purchased a new stake in shares of Elanco Animal Health in the first quarter valued at $891,000. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Elanco Animal Health in the first quarter valued at $111,000. Finally, Rakuten Securities Inc. lifted its holdings in shares of Elanco Animal Health by 81.2% in the first quarter. Rakuten Securities Inc. now owns 37,275 shares of the company's stock valued at $391,000 after purchasing an additional 16,700 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.